Request Information

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA)

  • Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is developing cancer treatments for areas which there is a high unmet medical need.

  • Our lead program, GDC-0084, a drug to treat glioblastoma multiforme, the most aggressive brain cancer, has completed phase 1 human trials with strong safety and early efficacy signals.

  • It is currently being prepared for phase 2 human trials.